Vanguard Group Inc. Acquires 153,575 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC)

Vanguard Group Inc. grew its holdings in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 666,995 shares of the company’s stock after buying an additional 153,575 shares during the quarter. Vanguard Group Inc.’s holdings in Vincerx Pharma were worth $3,375,000 at the end of the most recent reporting period.

Vincerx Pharma Price Performance

Shares of NASDAQ VINC opened at $0.61 on Monday. The business has a 50-day moving average of $0.65 and a 200-day moving average of $1.95. The stock has a market capitalization of $18.13 million, a price-to-earnings ratio of -0.34 and a beta of 1.47. Vincerx Pharma, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $9.37.

Vincerx Pharma (NASDAQ:VINC) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.12. On average, sell-side analysts expect that Vincerx Pharma, Inc. will post -0.62 EPS for the current year.

Vincerx Pharma Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.